Pharmaceutical Business review

Anesiva and Sigma-Tau sign marketing agreement for Zingo

Under the terms of the agreement, Sigma-Tau will oversee all necessary regulatory filings, and will be responsible for all marketing and sales of Zingo in their territory. The agreement between Anesiva and Sigma-Tau includes an upfront payment to Anesiva and transfer price, as well as milestone payments.

John McLaughlin, CEO of Anesiva, said: “This licensing agreement covers the majority of Europe and we are currently in advanced discussions with other potential partners for certain additional countries.”